- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.10. | From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama | ||
| 27.10. | Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy | ||
| 27.10. | Parkinson's-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs | ||
| 27.10. | Corxel claims oral obesity drug is in the 'right lane' as biotech plans SPAC route to Nasdaq | ||
| 27.10. | Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail | ||
| 27.10. | GSK's B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial | ||
| 27.10. | BMS joins 3-year partnership to boost participation in cancer trials | ||
| 26.10. | Boehringer, Microsoft team up to explore digital patient twins for clinical trials | ||
| 26.10. | Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing | ||
| 26.10. | Windward Bio | ||
| 26.10. | ESMO: Why Incyte sees itself 'neck and neck' with RevMed in KRAS G12D pancreatic cancer race | ||
| 26.10. | Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing | ||
| 26.10. | ESMO: Genmab posts phase 3 win for Elahere rival, ahead of 'very interesting' data from Merus buyout | ||
| 26.10. | BioNTech sees 'limited' benefit to ADC after phase 3 reveals modest efficacy, ILD cases | ||
| 26.10. | BMS sheds light on patient death in CAR-T trial, wants to get program back on track | ||
| 26.10. | ESMO: Tango trims headcount after impressing analysts with 'highly synergistic' RevMed combo | ||
| 25.10. | ESMO: J&J exec says RIPTAC readout is 'best data we've ever seen' for a prostate cancer drug | ||
| 25.10. | ESMO: AstraZeneca exec insists phase 3 ADC data 'robust' enough for regulators despite PFS miss | ||
| 25.10. | ESMO: Roche touts 'convincing' phase 3 KRAS data after win over rivals | ||
| 24.10. | 'It is what it is': Merck exec unruffled by 'unfortunate' leak of ESMO cancer vaccine data | ||
| 24.10. | ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space | ||
| 23.10. | Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions | ||
| 23.10. | EQT buys molecular diagnostics specialist Qiagen in a €10.8B deal | ||
| 23.10. | Gilead to pay $1.3B upfront for PepStar's oral IL-23 challenger to J&J's Icotyde | ||
| 23.10. | Bolt Biotherapeutics makes inflammation play with Prana reverse merger, $120M financing |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.